Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA
Negma Group has converted 130convertible bonds in Oxurion resulting in a EUR 325,000capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5billion.
Leuven, BELGIUM,Boston, MA, US–November 11, 2022– 07.00 PM CET – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), announces the below information, following the issuance of 16,250,000 new ordinary shares on November 7, 2022, for a total amount of EUR 325,000, as the result of the conversion of 130 class B convertible bonds, pursuant to the Capital Commitment entered into with Negma Group.
Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 109,075,765 outstanding ordinary shares carrying voting rights (compared to 92,825,765 outstanding ordinary shares previously). This number will be used as the denominator for the calculation of the percentages of shareholdings.
Therefore, Oxurion publishes the following updated information:
| 72,981,161.32 |
| 109,075,765 |
| 109,075,765 |
| |
|
END
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.
Important information about forward-looking statements
Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.
For further information please contact:
Oxurion NV Tom Graney Chief Executive Officer Tel: +32 16 75 13 10 tom.graney@oxurion.com Michaël Dillen Chief Business Officer Tel: +32 16 75 13 10 michael.dillen@oxurion.com | US Conway Communications Beth Kurth bkurth@conwaycommsir.com ICR Westwicke Christopher Brinzey Tel: +1 617 835 9304 chris.brinzey@westwicke.com |
1Press release Oxurion, 06/04/2021 and Press release Oxurion, 02/09/2022
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Belships ASA: Minutes of Annual General Meeting8.5.2024 17:00:00 CEST | Press release
The Annual General Meeting in Belships ASA was held today 8 May 2024. All matters were approved as set out in the Notice of Annual General Meeting. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachment Belships ASA - Minutes of AGM 2024
AMG Announces Results of the Annual General Meeting8.5.2024 16:49:24 CEST | Press release
Amsterdam, 8 May 2024(Regulated Information) --- AMG Critical Materials N.V. (“AMG”, EURONEXT AMSTERDAM: “AMG”) is pleased to announce that during its Annual General Meeting held on May 8, 2024, shareholders approved all agenda items presented, including the expansion of the Management Board from three to four members. Mr. Michael Connor was appointed to the Management Board as Chief Corporate Development Officer for a term of four years, with effect from May 8, 2024. During the meeting, Mr. Jackson Dunckel was reappointed as Chief Financial Officer for an additional term of four years, beginning May 8, 2024. In addition, Dr. Donatella Ceccarelli was reappointed as a member of the Supervisory Board for a term of two years, with effect from May 8, 2024. Given the rotation schedule of the Supervisory Board and the retirement in 2025 of two longstanding members, Professor Hanke and Mr. Depp, the Supervisory Board resolved to expand its resources to create a Board with seven members. Durin
First quarter results8.5.2024 16:42:54 CEST | Press release
Good results despite challenging reservoir position Landsvirkjun‘s profit from core operations amounted to 77.4 million USD for the first quarter of 2024 and cash flow from operations amounted to 101 million USD. Challenges in the company's reservoir levels and the resulting curtailment had a slight impact on Landsvirkjun's performance for the quarter. The company‘s financial position has never been better, with an equity ratio of 65.9% and a leverage ratio of 1.3x EBITDA. Hörður Arnarson, CEO: „Landsvirkjun‘s performance for the first quarter remained good, in spite of challenging circumstances. Following two exceptional operational years in the company's history, the results remain strong. Profit from core operations amounted to 77.4 million US dollars for the quarter, decreasing by nearly 29% from the same period last year. Cash flow from operations amounted to 101 million USD, decreasing by almost 30%. Both profit from core operations and cash flow from operations nevertheless held
AMG Announces Final 2023 Dividend8.5.2024 16:35:41 CEST | Press release
Amsterdam, 8 May 2024(Regulated Information) --- AMG Critical Materials N.V. (“AMG”, EURONEXT AMSTERDAM: “AMG”) is pleased to announce that during the Annual General Meeting, held on May 8, 2024, AMG's shareholders approved the payment of a dividend of €0.60 per ordinary share over the financial year 2023. The interim dividend of €0.40, paid on August 9, 2023, was deducted from the amount distributed to shareholders. The final dividend per ordinary share therefore amounts to €0.20. Payment of the final dividend will be completed on or around May 15, 2024, to shareholders of record on May 13, 2024. The ex-dividend date is May 10, 2023. Dutch withholding tax will be deducted from the dividend at a rate of 15%. This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. This press release contains regulated information as defined in the Dutch Financial Markets Supervision Act (Wet op het financieel toezicht). About AMG AMG's mission
BW Energy: Hibiscus South pilot well confirms hydrocarbons8.5.2024 16:35:00 CEST | Press release
BW Energy: Hibiscus South pilot well confirms hydrocarbons BW Energy is pleased to announce that the DHBSM-2P pilot well confirms that the Hibiscus South deposit extends into the northern part of the field with good reservoir quality, increasing reserve estimates. The Company plans to complete the well as a production well later in 2024. The DHBSM-2P pilot was drilled from the MaBoMo production platform to a total depth of 5,130 metres. The target area is located approximately 3.2 kilometres west-northwest of the MaBoMo and was drilled by the Borr Norve jack-up rig. Evaluation of logging data, sample examination and formation pressure measurements confirm approximately 25 metres of pay in an overall hydrocarbon column of 35 metres in the Gamba formation. The well data provides additional confirmation that the Hibiscus South structure is a separate accumulation with a deeper oil-water contact than the nearby Hibiscus Field. This will enable the Company to book additional reserves not cu